Published on 5 May 2023 on Zacks via Yahoo Finance
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
Ultragenyx Pharmaceutical Inc. RARE incurred a loss of $2.33 per share in first-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $1.97. The company reported a $2.19 per share loss in the year-ago quarter.
Ultragenyx’s total revenues amounted to $100 million in the first quarter, up 25.7% year over year. The top line, however, missed the Zacks Consensus Estimate of $105 million.
Shares of Ultragenyx have lost 1.2% in the year so far compared with the industry’sdecline of 6.2%.